Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria.
Annals of the rheumatic diseases (Impact Factor: 10.38). 04/2010; 69(4):638-43. DOI: 10.1136/ard.2009.123976
Source: PubMed

ABSTRACT To summarise existing evidence on a target oriented approach for rheumatoid arthritis (RA) treatment.
We conducted a systematic literature search including all clinical trials testing clinical, functional, or structural values of a targeted treatment approach. Our search covered Medline, Embase and Cochrane databases until December 2008 and also conference abstracts (2007, 2008).
The primary search yielded 5881 citations; after the selection process, 76 papers underwent detailed review. Of these, only seven strategic clinical trials were extracted: four studies randomised patients to routine or targeted treatment, two compared two different randomised targets and one compared targeted treatment to a historical control group. Five trials dealt with early RA patients. All identified studies showed significantly better clinical outcomes of targeted approaches than routine approaches. Disability was reported in two studies with no difference between groups. Four studies compared radiographic outcomes, two showing significant benefit of the targeted approach.
Only few studies employed randomised controlled settings to test the value of treatment to a specific target. However, they provided unanimous evidence for benefits of targeted approaches. Nevertheless, more data on radiographic and functional outcomes and on patients with established RA are needed.

Download full-text


Available from: Johannes W J Bijlsma, Aug 25, 2015
  • Source
    • "In the clinical practice setting, however, little attention and guidance have been given about what to monitor, which assessments to use, and how to define response and remission of RA [1]. The Australian Rheumatology Association recommends using DAS28 to monitor patients receiving a biological agent in clinical practice [12]. In Australia, the Pharmaceutical Benefits Scheme (PBS) requires an assessment of treatment response based on ESR, CRP, or active joint count for the prescription of reimbursable biological disease-modifying antirheumatic drugs (bDMARD) [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. To investigate which rheumatoid arthritis (RA) disease activity measures are being collected in patients receiving glucocorticoids, non-biologic or biologic disease-modifying antirheumatic drugs (DMARDs) in Australian rheumatology practice. Methods. A retrospective audit of medical records was conducted from eight rheumatology practices around Australia. Each rheumatologist recruited 30 consecutive eligible patients into the review, 10 of whom must have been receiving a biological agent for rheumatoid arthritis. Disease activity measures and radiographic assessments were collected from each patient's last consultation. For biologic patients, disease activity measures were also collected from when the patient was first initiated on the biological agent. Results. At last consultation, the disease measures that were recorded most often were ESR (89.2%), haemoglobin (87.5%), and CRP (84.2%). DAS28 was infrequently recorded (16.3%). The rate of recording disease activity measures for patients receiving biologic DMARDs decreased over time (mean 27 months). Conclusion. This review has shown inconsistency of RA activity measures being recorded in Australian rheumatology clinical practice. An accurate assessment of the disease process is necessary to effectively target rheumatoid arthritis patients to treat in order to achieve optimal outcomes.
    05/2011; 2011:437281. DOI:10.5402/2011/437281
  • [Show abstract] [Hide abstract]
    ABSTRACT: Self-heating effects limit the performance of high-power AlGaN/GaN HFETs. Knowledge of the temperature in the active area of AlGaN/GaN HFETs is essential for optimizing device design, performance and reliability, however, direct measurement of this temperature is not readily achieved by IR techniques. Improved temperature information can be obtained by micro-Raman spectroscopy allowing temperature measurements with 1 μm spatial resolution, important for local device geometries in the micron/sub-micron dimension range. This novel approach allows fast temperature measurements with minimal influence on device performance. We illustrate the use of micro-Raman spectroscopy for thermal management and device failure assessment by studying effects of device design and substrate on temperature in active high-power AlGaN/GaN HFETs. Temperature evolution up to device failure was investigated.
    Device Research Conference, 2002. 60th DRC. Conference Digest; 02/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper addresses the problem of complex channel impulse response identification using δ-signed correlation method [Balakrishnan et al., 2001]. These types of correlation methods are simple, robust and computationally very efficient. In this paper, channel order estimation and selection of appropriate threshold value δ are considered. The threshold selection is formulated as a detection problem assuming that i.i.d. data are transmitted and the channel outputs are Gaussian. Simulation results demonstrating the robustness of the approach are shown.
Show more